Aerie Pharmaceuticals Inc., an ophthalmic pharmaceutical company, announced that its Chairman and CEO, Vicente Anido, PhD. has stepped down from his role as the company’s Chairman and Chief Executive Officer or as a director of the company after eight years, effective September 17, 2021.
In the meantime, the company has appointed Benjamin F. McGraw, III, Pharm.D. as its Interim Executive Chairman of the Board of Directors.
Aerie Pharmaceuticals is now searching for a new CEO following the appointment of Benjamin F. McGraw, while the Board of Directors intends to separate the roles of Chairman and CEO as a part of its succession plan in motion.
According to information obtained from the company’s website, Dr. McGraw has been a board member in Aerie since September 2014. He is currently Executive Chairman and Chief Executive Officer of TheraVida, Inc., a specialty pharmaceutical company.
Dr. McGraw said “On behalf of the Board, I would like to express our sincere appreciation to Vince for all his contributions over the years since Aerie was a private company through the public offering and into Aerie becoming a commercial stage company. Under his leadership, Aerie now has two clearly differentiated products on the market and we believe we have a very good portfolio of products in development.
“We believe the succession plan we have in place will serve the shareholders well. We have a strong board of directors and each one of them has committed to helping the Company during this transition,” Mcgraw added.
About Aerie Pharmaceuticals, Inc.
Aerie is an ophthalmic pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases.